Showing 4971-4980 of 6036 results for "".
- Glaukos Announces Positive Phase 3 Trial Results for iLink Epi-On Investigational Therapyhttps://modernod.com/news/glaukos-announces-positive-phase-3-trial-results-for-ilink-epi-on-investigational-therapy/2478917/Glaukos announced that U.S. phase 3 pivotal trial results for its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, known as Epi-on, met the study’s primary efficacy endpoint, demonstrating a statistically significant improvement in maximum corneal curvature (K
- Moderna’s Variant-Specific COVID-19 Vaccine Candidate Ready for Clinical Testinghttps://modernod.com/news/modernas-variant-specific-covid-19-vaccine-candidate-ready-for-clinical-testing/2478914/Moderna said that it has manufactured the initial batch of an updated version of its COVID-19 vaccine designed to better protect against the B.1.351 variant of SARS-CoV-2 first identified in South Africa. The company indicated late last month that it would be working on the variant-specific boost
- One-Dose J&J COVID-19 Vaccine Meets Criteria as Safe and Effective, FDA Report Findshttps://modernod.com/news/one-dose-jj-covid-19-vaccine-meets-criteria-as-safe-and-effective-fda-report-finds/2478912/Detailed information on a Johnson & Johnson candidate vaccine for COVID-19 raises no safety concerns, according to a report released early Wednesday, according to a USA Today
- NeurOptics Launches Virtual Pupillometry Education Platformhttps://modernod.com/news/neuroptics-launches-virtual-pupillometry-education-platform/2478910/NeurOptics has launched its Pupillometry Education Symposiums platform, which includes a series of both product and clinical-focused presentations that demonstrate the essential role pupillometry and the Neurological Pupil index (NPi) play in the assessment and screening of patients at risk of ne
- Pfizer, Moderna and J&J Tout Supercharged COVID-19 Vaccine Output, Eyeing Nearly 140 Million New Doses by Marchhttps://modernod.com/news/pfizer-moderna-and-jj-tout-supercharged-covid-19-vaccine-output-eyeing-nearly-140-million-new-doses-by-march/2478909/Pfizer, Moderna, and Johnson & Johnson execs say they’re working all the angles on increasing COVID-19 vaccine production and expect to amp up weekly deliveries by tens of millions by the end of March, according to a FiercePharma
- FDA Outlines Faster Path for COVID-19 Vaccines That Tackle New Variantshttps://modernod.com/news/fda-outlines-faster-path-for-covid-19-vaccines-that-tackle-new-variants/2478898/The FDA on Monday issued new guidance confirming that drugmakers will not have to perform large-scale trials for new COVID-19 vaccines or booster shots developed to combat new variants of SARS-CoV-2. “At this time, available information suggests that the FDA-authorized vaccines remain effec
- UK Real-World Data Show COVID-19 Vaccine Linked to Lower Infection, Hospitalization Rateshttps://modernod.com/news/uk-real-world-data-show-covid-19-vaccine-linked-to-lower-infection-hospitalization-rates/2478899/Data from new analyses were released Monday shedding light on the short-term impacts of COVID-19 vaccinations in the UK. One analysis from Public Health England’s (PHE) SIREN study appears to corroborate early evidence that Pfizer and BioNTech’s vaccine BNT162b2 offers high levels of
- PYC Therapeutics Accelerates Its Pipeline of RNA Therapeutics for Ocular Diseaseshttps://modernod.com/news/pyc-therapeutics-accelerates-its-pipeline-of-rna-therapeutics-for-ocular-diseases/2478892/PYC Therapeutics announced updates to its programs and outlined its 2021-2022 corporate objectives. PYC is initially targeting inherited ocular diseases, for which it has three preclinical candidates in development. “This year we are focused on transforming PYC Therapeutics into a U.S.-bas
- Pfizer’s COVID-19 Vaccine Stimulates Lower Antibody Response Against B.1.351 Strainhttps://modernod.com/news/pfizers-covid-19-vaccine-stimulates-lower-antibody-response-against-b-1-351-strain/2478888/Preliminary findings from an in vitro study published Wednesday in the NEJM showed that Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 elicited roughly two-thirds lower levels of neutralizing antibodies against a highly transmissible SARS-CoV-2 variant that was first spotted in So
- Ophthalmic Fundraising Activity Soars in Face of Pandemichttps://modernod.com/news/ophthalmic-fundraising-activity-soars-in-face-of-pandemic/2478884/The ophthalmic market continues to expand and attract funding from investors. There were more deals in 2020 than the two previous years, and transactions totaled $8.6 billion, according to a new Market Scope report. Retina is the largest ophthalmic market sector, driven by a booming pharma